Insys Therapeutics, Inc. (NASDAQ:INSY) has been assigned a consensus recommendation of “Hold” from the seven research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $12.67.

Several research analysts have issued reports on INSY shares. Zacks Investment Research upgraded shares of Insys Therapeutics from a “sell” rating to a “strong-buy” rating and set a $15.00 price target on the stock in a research report on Wednesday, July 12th. TheStreet lowered shares of Insys Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, August 21st. Jefferies Group LLC restated a “buy” rating and issued a $14.00 price target on shares of Insys Therapeutics in a research report on Friday, June 9th. Royal Bank Of Canada decreased their price target on shares of Insys Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, August 4th. Finally, BidaskClub lowered shares of Insys Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, August 11th.

Shares of Insys Therapeutics (NASDAQ:INSY) opened at 8.81 on Friday. Insys Therapeutics has a one year low of $8.70 and a one year high of $15.06. The firm’s 50-day moving average price is $9.45 and its 200-day moving average price is $11.15. The firm’s market cap is $640.45 million.

Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.12. The firm had revenue of $42.60 million for the quarter, compared to analyst estimates of $36.90 million. Insys Therapeutics had a negative net margin of 9.63% and a negative return on equity of 3.02%. The firm’s quarterly revenue was down 38.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.13 earnings per share. Equities research analysts expect that Insys Therapeutics will post ($0.29) earnings per share for the current fiscal year.

In other news, CEO Saeed Motahari acquired 5,500 shares of the stock in a transaction on Thursday, August 10th. The shares were purchased at an average cost of $8.92 per share, for a total transaction of $49,060.00. Following the transaction, the chief executive officer now owns 15,400 shares in the company, valued at approximately $137,368. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder John N. Kapoor Trust Dated Sept acquired 17,500 shares of the stock in a transaction on Friday, August 11th. The shares were purchased at an average price of $8.93 per share, for a total transaction of $156,275.00. Following the completion of the transaction, the insider now owns 31,982 shares in the company, valued at approximately $285,599.26. The disclosure for this purchase can be found here. Insiders own 67.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of INSY. Thrivent Financial For Lutherans purchased a new position in Insys Therapeutics during the 1st quarter worth approximately $1,058,000. Point72 Asset Management L.P. grew its position in Insys Therapeutics by 24.8% during the 1st quarter. Point72 Asset Management L.P. now owns 435,000 shares of the specialty pharmaceutical company’s stock worth $4,572,000 after purchasing an additional 86,373 shares in the last quarter. Alliancebernstein L.P. grew its position in Insys Therapeutics by 128.6% during the 2nd quarter. Alliancebernstein L.P. now owns 140,840 shares of the specialty pharmaceutical company’s stock worth $1,782,000 after purchasing an additional 79,220 shares in the last quarter. First Trust Advisors LP grew its position in Insys Therapeutics by 105.3% during the 1st quarter. First Trust Advisors LP now owns 147,788 shares of the specialty pharmaceutical company’s stock worth $1,553,000 after purchasing an additional 75,817 shares in the last quarter. Finally, Quantitative Investment Management LLC purchased a new position in Insys Therapeutics during the 2nd quarter worth approximately $879,000. Hedge funds and other institutional investors own 25.45% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Insys Therapeutics, Inc. (INSY) Given Average Recommendation of “Hold” by Analysts” was posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/23/insys-therapeutics-inc-insy-given-average-recommendation-of-hold-by-analysts.html.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.